Purple Biotech to paint with Immunorizon's tri-specific antibodies in small M&A deal

Purple Biotech is adding Immunorizon’s tri-specific antibodies to its paint palette in an acquisition that could reach $100 million.

The M&A deal, announced Thursday morning, will see privately held Immunorizon come under the wing of Purple, which focuses on tumor immune evasion and drug resistance. Purple has two lead assets in the pipeline: NT219 and CM24 for solid tumors and pancreatic ductal adenocarcinoma, respectively.